Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LLY
LLY logo

LLY News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

LLY News

Eli Lilly's Stock Soars to All-Time High Amid GLP-1 Drug Success

13h agoNASDAQ.COM

Eli Lilly's Promising Future in Obesity Drug Market

16h agoNASDAQ.COM

Eli Lilly Shares Reach All-Time High Following Analyst Upgrade

2h agoFool

Eli Lilly Shareholders Set for More Gains as Analyst Raises Price Target

2h agoNASDAQ.COM

Nasdaq Leads Market Down as Samsung Earnings Hit AI Stocks

5h agoYahoo Finance

Surging Demand for GLP-1 Drugs Benefits Medical Device Companies

7h agoFool

Nasdaq Leads Market Decline as Samsung Earnings Hit AI Stocks

7h agoYahoo Finance

Novo Nordisk Faces Challenges but Optimistic Outlook Ahead

8h agoFool

LLY Events

07/07 09:31
Eli Lilly Canada Launches Mounjaro for Pediatric Diabetes Treatment
Eli Lilly Canada announced that Mounjaro is now indicated as an adjunct to diet and exercise to improve glycemic control in pediatric patients living with type 2 diabetes aged 10 to 17 years. "Managing pediatric type 2 diabetes requires dedicated, evidence-based options that support both patients and their families," said Mathilde Merlet, General Manager and President, Eli Lilly Canada. "This approval provides clinicians and youth living with type 2 diabetes with an additional tool to help manage this complex chronic condition, reflecting our ongoing commitment to bringing therapeutic innovations to Canadians."
06/30 14:00
AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly.NEW UNIT:Francessca Vasquez, Vice President of Frontier AI Engineering and Services, AWS, said in a blog post, "I'm excited to announce that we are meeting that demand by creating a dedicated AWS Forward Deployed Engineering organization. Backed by a $1B investment, the AWS FDE model is different in three key ways: it is agentic-first, it compresses timelines from months to days, and it is designed so customers are self-sufficient when a deployment ends. AWS FDE embeds AWS frontier teams-working with purpose-built agents-directly inside customer teams. These experienced engineers, many of whom build our AWS AI services, partner with a customer's business, engineering, and security teams to build and deploy production AI systems with their data, governance, and processes. Unlike traditional consulting that assesses, recommends, and treats each deployment as a standalone project, AWS FDE builds for the long term. Customers leave AWS FDE deployments with both new solutions and new engineering capabilities. Along with agentic systems running in their own AWS environment, they gain lasting AI skills, workflows, and patterns they can use to innovate independently. Deployments are structured around shared goals and business results, not billable hours. When customers succeed, we succeed."CLAUDE SCIENCE:Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a broader push to become a major platform in biology and life sciences backed by rapidly growing scale and financial resources comparable to leading drug companies, STAT's Matthew Herper and Brittany Trang. Publicly traded companies in the pharmaceutical space include AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Rocheand Sanofi.CLAUDE APPS GETAWAY:Anthropic introduced the Claude apps gateway for Amazon Bedrock and Google Cloud. Previously, running Claude Code on these platforms has meant provisioning a cloud credential per developer, manually pushing settings to every laptop, and standing up separate tooling to see per-developer spend. The gateway is a self-hosted control plane that gives you corporate SSO login, centrally enforced policy, role-based access, and per-user cost attribution for Claude Code. The gateway is run as a single stateless container deployed on Linux and backed by a PostgreSQL database. It holds your upstream credential, authenticates developers against your identity provider, distributes and enforces managed settings, and reports per-user usage to a collector you operate. Onboarding a developer means adding them to your Identity Provider. Offboarding means removing them.Meanwhile, Anthropic said that, starting Monday, Claude models are generally available in MicrosoftFoundry, hosted on Azure. "Claude runs in your Azure environment with the authentication, billing, and governance controls your teams already use," Anthropic said. "You can choose where inference is processed, including a US data zone for teams with data residency requirements. Anthropic operates the inference and is the data processor."

LLY Monitor News

Eli Lilly's Obesity Drug Market Growth Boosts Stock

Jul 07 2026

Eli Lilly Receives Positive EMA Opinion for Jaypirca in CLL Treatment

Jun 26 2026

Eli Lilly's Foundayo Shows Promising Weight Loss Results

Jun 08 2026

Eli Lilly's Acquisition Strategy Boosted by GLP-1 Drug Success

Jun 05 2026

Eli Lilly's Acquisition Strategy Boosted by GLP-1 Drug Success

Jun 04 2026

Eli Lilly Expands Coverage for Obesity Medications

May 28 2026

Eli Lilly's Drug Trials Show Promising Weight Loss Results

May 13 2026

Eli Lilly and Roche Collaborate on Alzheimer's Blood Test

May 12 2026

LLY Earnings Analysis

Eli Lilly Q3 2025 Earnings: Revenue Growth & Strategic Gains- Intellectia AI™
8 months ago
Eli Lilly Q2 2025 Earnings: Record Growth & Future Prospects- Intellectia AI™
11 months ago
Eli Lilly's Triumph in Q4 2024 - Intellectia AI™
1 years ago
Eli Lilly and Company Reports Third Quarter 2024 Financial Results
1 years ago

People Also Watch